Table 4.
Effect of antibiotics on disease activity in patients with ENT involvement and S. aureus colonization
| Disease activity | Antibiotic treatment | P value | |
|---|---|---|---|
| Yes (n = 28) | No (n = 12) | ||
| Systemic symptoms | |||
| History of one or more relapses, n (%) | 18 (47.4%) | 4 (10.5%) | 0.635 |
| Relapse number per patient years, median (IQR)a | 0.11 (0–0.18) | 0.17 (0.02–0.26) | 0.346 |
| BVAS3 last visit, median (IQR) | 1 (0–4) | 1 (0–4) | 0.932 |
| Local symptoms | |||
| History of one or more ENT relapses, n (%)a | 9 (33.3%) | 3 (11.1%) | 0.438 |
| Development of saddle nose deformity during follow-up, n (%)a | 4 (12.1%) | 0 (0%) | 0.367 |
Values are median (interquartile range IQR) or n (%)
AAV ANCA-associated vasculitis, ANCA anti-neutrophilic cytoplasmic autoantibody, BVAS3 Birmingham vasculitis activity score version 3, ENT ear nose and throat. Antibiotic treatment is defined as at least one prescription of cotrimoxazole, azithromycin and/or mupirocin aimed at S. aureus eradiation
aMore than 10% missing in analysis. For an overview of the number of included patients per analysis, see supplementary table B